IDO Peptid Vaccination in Combination With Immune Stimulating Agent Aldara and the Adjuvant Montanide, for Treatment of Patients With Locally Advanced or Metastatic Non Small-cell Lung Cancer. A First-in-man Phase I Trial.

Trial Profile

IDO Peptid Vaccination in Combination With Immune Stimulating Agent Aldara and the Adjuvant Montanide, for Treatment of Patients With Locally Advanced or Metastatic Non Small-cell Lung Cancer. A First-in-man Phase I Trial.

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Oct 2017

At a glance

  • Drugs IO 101 (Primary) ; Imiquimod; Montanide ISA-51
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 12 Oct 2017 Five-year follow-up data were presented last month at the ESMO Congress 2017, as reported in an IO Biotech media release.
    • 12 Oct 2017 Results published in an IO Biotech Media Release
    • 12 Oct 2017 Results from this trial were published in Clinical Cancer Research, as reported in an IO Biotech media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top